Biomarkers in hepatocellular carcinoma: diagnosis, prognosis and treatment response assessment
Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …
worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and …
PD-1/PD-L1 targeting in breast cancer: the first clinical evidences are emerging—a literature review
Recently, the development of immunotherapy through the immune checkpoint blockade led
to long-lasting responses in several types of cancers that are refractory to conventional …
to long-lasting responses in several types of cancers that are refractory to conventional …
Multiomics prediction of response rates to therapies to inhibit programmed cell death 1 and programmed cell death 1 ligand 1
Importance Therapies to inhibit programmed cell death 1 and its ligand (anti–PD-1/PD-L1)
provide significant survival benefits in many cancers, but the efficacy of these treatments …
provide significant survival benefits in many cancers, but the efficacy of these treatments …
[HTML][HTML] Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis
C Boman, I Zerdes, K Mårtensson, J Bergh… - Cancer Treatment …, 2021 - Elsevier
Introduction Programmed cell death ligand 1 (PD-L1) expression is predictive for benefit
from immunotherapy in several human malignancies including triple negative breast cancer …
from immunotherapy in several human malignancies including triple negative breast cancer …
Low-dose anti-angiogenic therapy sensitizes breast cancer to PD-1 blockade
Purpose: Despite its enormous successes, the overall response rate of cancer
immunotherapy remains suboptimal, especially in breast cancer. There is an increased …
immunotherapy remains suboptimal, especially in breast cancer. There is an increased …
A pan-cancer analysis of CD161, a potential new immune checkpoint
X Zhou, J Du, C Liu, H Zeng, Y Chen, L Liu… - Frontiers in …, 2021 - frontiersin.org
Background CD161, encoded by killer cell lectin-like receptor B1 gene, is a newly reported
candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade …
candidate inhibitor of tumour-infiltrating T cells. Antibody-mediated CD161 blockade …
Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
G Griguolo, T Pascual, MV Dieci, V Guarneri… - … for immunotherapy of …, 2019 - Springer
Growing evidence suggests a clear role of the host immune system in HER2+ breast cancer.
In addition, HER2+ breast cancer is generally considered more immunogenic than hormone …
In addition, HER2+ breast cancer is generally considered more immunogenic than hormone …
Next-generation therapies for adrenocortical carcinoma
Almost one decade ago, etoposide, doxorubicin, cisplatin and mitotane (EDP-M) has been
established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC) …
established as first-line systemic therapy of metastatic adrenocortical carcinoma (ACC) …
Early triple negative breast cancer: conventional treatment and emerging therapeutic landscapes
A Diana, F Carlino, E Franzese, O Oikonomidou… - Cancers, 2020 - mdpi.com
Triple negative breast cancers (TNBCs) are characterized by worse prognosis, higher
propensity to earlier metastases, and shorter survival after recurrence compared with other …
propensity to earlier metastases, and shorter survival after recurrence compared with other …
[HTML][HTML] Profiling of immune features to predict immunotherapy efficacy
Immune checkpoint blockade (ICB) therapies exhibit substantial clinical benefit in different
cancers, but relatively low response rates in the majority of patients highlight the need to …
cancers, but relatively low response rates in the majority of patients highlight the need to …